Abstract 495P
Background
Osimertinib has been established as standard treatment for patients with advanced EGFR-mutated NSCLC. We assessed the clinical relevance of EGFR mutation tracking in plasma circulating tumor DNA (ctDNA) after initiation of osimertinib therapy in patients who were pre-treated with EGFR-tyrosine kinase inhibitors (TKIs).
Methods
Plasma samples of 106 patients with advanced EGFR-mutated NSCLC who received second-line osimertinib after detection of T790M mutation in plasma ctDNA and/or tissue re-biopsy were collected under osimertinib therapy. Plasma ctDNA was tested for EGFR deletions in exon 19, L858R, L861Q, S768I, T790M and C797S mutations using droplet digital PCR (ddPCR). Primary endpoint was progression-free survival (PFS). Univariate and multivariable Cox proportional hazard models were used to evaluate the risk of progression.
Results
In 57 out of 106 patients plasma samples were available within the first 8 weeks after osimertinib therapy initiation. Within this time frame, the activating mutation remained detectable in plasma of 19/57 patients (33%) and the T790M mutation in 8/57 patients (14%). The C797S mutation was not detectable within 8 weeks after osimertinib start. Patients with persistence of the activating EGFR mutation in plasma ctDNA within 8 weeks after osimertinib initiation had a shorter PFS compared to patients who had lost the activating EGFR mutation (median PFS 3.4 versus 26.9 months; hazard ratio [HR] 6.17, 95% confidence interval [CI] 3.03-12.56, p < 0.0001). Similarly, detection of T790M in plasma ctDNA was also associated with shorter PFS (median PFS 7.0 versus 19.0 months; HR 2.32, 95% CI 1.00-5.37, p = 0.05). Multivariable analysis using a stepwise backward elimination model demonstrated that persistence of activating EGFR mutations and T790M in plasma ctDNA remained significant predictors of shorter PFS after adjusting for clinical parameters and T790M.
Conclusions
Our results show that tracking of activating EGFR mutations during osimertinib therapy is clinically relevant. Detection of activating EGFR mutations in plasma ctDNA 8 weeks after osimertinib initiation predicts shorter PFS of second-line treatment with osimertinib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
A. Buder: Honoraria (self): AstraZeneca. M.J. Hochmair: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim. M. Filipits: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
YO10 - Rectal Follicular Dendritic Cell Sarcoma
Presenter: Kripa Bajaj
Session: Poster display session
Resources:
Abstract
YO11 - Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
Presenter: Lianyuan Tao
Session: Poster display session
Resources:
Abstract
YO12 - Case report of Hepatic EBV-associated smooth muscle tumor in AIDS patient
Presenter: Gorawich Kerkarchachai
Session: Poster display session
Resources:
Abstract
YO13 - IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy
Presenter: Wasamol Mahaparn
Session: Poster display session
Resources:
Abstract
YO14 - Urachal Adenocarcinoma: Case Report
Presenter: Michelle Joane Alcantara
Session: Poster display session
Resources:
Abstract
YO15 - Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO16 - Clear cell RCC with synchronous metastasis at transplanted kidney and bone in patient post Cadaveric donor kidney transplantation
Presenter: Punyaporn Cheewasathianchai
Session: Poster display session
Resources:
Abstract
YO17 - Serous ovarian cancer treated with palbociclib and letrozole
Presenter: Dai Wee Lee
Session: Poster display session
Resources:
Abstract
YO18 - A patient with Peutz-Jegher syndrome who incidentally found sex cord stromal tumor: a case report
Presenter: Pongput Pimsa
Session: Poster display session
Resources:
Abstract
YO19 - A case of CLL/SLL with transdifferentiation to dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm:The missing link?
Presenter: Yanping Chen
Session: Poster display session
Resources:
Abstract